过去一年中添加的文章，按日期排序
… -029 A systematic review of combined poly (ADP-ribose) polymerase inhibitor and androgen receptor antagonists in metastatic castration-resistant prostate cancer
YH Wang, KC Chang, HY Chen - 2024 - ejhp.bmj.com
219 天前 - … According to latest practice guideline, concurrent administration of poly (ADP-…
therapy (ADT) may have synergistic efficacy for metastatic castrationresistant prostate cancer (…
therapy (ADT) may have synergistic efficacy for metastatic castrationresistant prostate cancer (…
[HTML][HTML] … pathway at a cancer center for the administration of radiometabolic therapy with 177Lu-PSMA in patients with metastatic castration-resistant prostate cancer
C Avila, T Cadavid, MC Martínez, H Varela… - … Therapy, 2024 - ncbi.nlm.nih.gov
226 天前 - … Medicine Group of the NCI and is the result of adjustments and improvements in
the care process and the updating … a systematic method for the administration of 177Lu-PSMA …
the care process and the updating … a systematic method for the administration of 177Lu-PSMA …
How the Management of Biochemical Recurrence in Prostate Cancer Will Be Modified by the Concept of Anticipation and Incrementation of Therapy
A Sciarra, V Santarelli, S Salciccia, M Moriconi… - Cancers, 2024 - mdpi.com
276 天前 - … , and treatment modalities of BCR, with a focus on the latest … metastases (non-metastatic
castration-resistant PC). Patients with high-risk BCR benefit from early systemic therapy…
castration-resistant PC). Patients with high-risk BCR benefit from early systemic therapy…
FoundationOne CDx Is Approved to Help Identify Patients Who Are Eligible for Selpercatinib.
C Ryan - Oncology Nursing News, 2023 - go.gale.com
361 天前 - … on or after previous systemic treatment, or who have no satisfactory alternative …
metastatic castration-resistant prostate cancer.4 References 1. US Food and Drug Administration …
metastatic castration-resistant prostate cancer.4 References 1. US Food and Drug Administration …